UNICYCIVE THERAPEUTICS INC (UNCY)
Health Care · Clinical-stage kidney disease therapeutics · NASDAQ
A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
What UNICYCIVE THERAPEUTICS INC does
Unicycive Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies for kidney disease. The company's pipeline consists of two main programs: oxylanthanum carbonate, a next-generation phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate for acute kidney injury treatment. The company licenses technologies and drugs to pursue development, regulatory approval, and commercialization, with an initial focus on U.S. markets.
Themes: kidney disease, hyperphosphatemia, acute kidney injury (AKI), clinical-stage biopharma
Fundamentals
- Price$5.63 as of 2026-08-21 close
- Market cap$157M as of 2026-08-21
- 1-year return+32.5% 2025-08-21 close $4.25 → 2026-08-21 close $5.63
- P/En/a negative earnings
- Net margin-4159.1% as of 2026-08-24
- ROE-131.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.76 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
Dividend: pays a dividend.
How UNCY compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which UNCY reported a dividend payment is FY2024, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2024 ratio would not describe UNCY today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2024) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How UNICYCIVE THERAPEUTICS INC looks technically
UNICYCIVE THERAPEUTICS INC (UNCY) is trading 11.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 38 trading days ago. It is 35.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 11.3% below its 200-day average, the long-term trend line — a long-term downtrend | -11.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.81 | $5.81 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.34 | $6.34 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 4.71. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 13 trading days ago — a "death cross", a bearish long-term signal | 13 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.92 to $5.85) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 76.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.74 | $8.74 |
|---|---|---|
| From the 52-week high | it is 35.6% below its 52-week high (its highest price of the past year) | -35.6% |
| Above the 52-week low | it is 51.8% above its 52-week low (its lowest price of the past year) | +51.8% |
| Below the 52-week high | it is 35.6% below its highest point of the past year | 35.6% |
| Since a 20-day breakout | it made a new 20-day low about 38 trading days ago | 38 sessions |
| Since a 55-day breakout | it made a new 55-day low about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $87.30 (set on 2021-07-13) | $87.30 |
| Given back of the 52-week move | over the past year its closes ranged ($3.74 to $8.56), and it has given back a bit over half of its rise from last year’s low — 61% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.43 to $5.58. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 60.8% |
| From the all-time high | it is 93.6% below its all-time high | -93.5% |
| Nearest price level | it is trading 3.7% below a resistance level at $5.84 — a price it turned at three times since 2025-01-13, most recently on 2026-07-21. Since 2024-08-21 it has 6 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.7% |
| All-time low | its lowest closing price on record is $2.02 (set on 2024-08-13) | $2.02 |
| Above the all-time low | it is 178.7% above its all-time low | +178.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 46th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3385 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3385 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.73 and $5.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.73 – $5.24 – $5.76 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 2.1 daily ranges below its 200-day average price (11.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.23× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 16.0% since the prior reading | -16.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.8% above the previous close 7 sessions ago and has not traded back through the level it left behind at 5 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.8% |
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.4 percentage points (the stock lost 1.1% while the market gained 2.3%) | -3.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.3 percentage points (the stock lost 26.2% while the market gained 3.1%) | -29.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 21.4 percentage points (the stock lost 10.4% while the market gained 11.1%) | -21.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.0 percentage points (the stock gained 32.5% while the market gained 20.5%) | +12.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.5% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.25 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -10.0% |
|---|
Price levels it has turned at before
UNCY last closed at $5.63 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.84 | Resistance | 3.7% above the last close | turned there three times · 2025-01-13 to 2026-07-21 |
| $5.37 | Support | 4.6% below the last close | turned there five times · 2025-05-23 to 2026-01-05 |
| $6.04 | Resistance | 7.3% above the last close | turned there five times · 2024-11-11 to 2026-03-30 |
| $5.11 | Support | 9.2% below the last close | turned there three times · 2025-01-28 to 2025-11-21 |
| $4.98 | Support | 11.5% below the last close | turned there four times · 2024-09-20 to 2025-08-15 |
| $6.30 | Resistance | 11.9% above the last close | turned there twice · 2024-12-24 to 2025-12-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $4.71.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · trendless / choppy (low ADX) · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$32.40 range $13.00 – $72.00; median $27.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for UNCY
- Consensus EPS estimate-$0.3189 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of losses and expectation of continued operating losses as a clinical-stage company.","Substantial reliance on the success of two specific product candidates, oxylanthanum carbonate and UNI-494.","Significant capital requirements for clinical trials and regulatory approval processes."]
What changed in the latest 10-Q
AI-assisted comparison of UNCY's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) includes financial statements as of March 31, 2026, compared to older filing (2025-11-12) which covered period ended September 30, 2025
- Newer filing shows cash and cash equivalents of $37,371 thousand as of March 31, 2026, compared to $29,198 thousand as of December 31, 2025
- Newer filing reports marketable securities of $17,215 thousand as of March 31, 2026, compared to $12,071 thousand as of December 31, 2025
- Newer filing shows warrant liability of $21,695 thousand as of March 31, 2026, compared to $16,915 thousand as of December 31, 2025
- Newer filing reports accumulated deficit of $140,648 thousand as of March 31, 2026, compared to $127,825 thousand as of December 31, 2025
- Newer filing shows net loss of $12,823 thousand for three months ended March 31, 2026, compared to net income of $570 thousand for three months ended March 31, 2025
- Newer filing reports change in fair value of warrant liability of negative $4,780 thousand for Q1 2026, compared to positive $8,348 thousand for Q1 2025
- Newer filing shows issuance of common stock for cash of $19,569 thousand (net) in Q1 2026, with 3,123,537 shares issued
- Newer filing reports common shares outstanding of 25,237,782 as of March 31, 2026, compared to 22,114,245 as of December 31, 2025
- Newer filing shows operating lease liability – long term of $217 thousand as of March 31, 2026, which was zero as of December 31, 2025
- Newer filing reports initial recognition of right-of-use assets of $908 thousand in supplemental cash flow information
- Removed:
- Older filing includes extensive forward-looking statements section and overview narrative discussion; newer filing appears to show only financial tables and notes, with narrative content not provided in excerpt
- Reworded:
- Balance sheet date changed from December 31, 2025 to March 31, 2026 in newer filing
- Income statement comparison periods changed from three months ended March 31, 2025 vs. 2026 in newer filing
- Stockholders' equity statement now includes 'Accumulated Comprehensive Income (Loss)' column in newer filing for 2026 period
- Cash flows statement header updated to show 'Three Months Ended March 31' for both 2025 and 2026 periods in newer filing
- Notes:
- The older filing excerpt appears truncated and contains primarily narrative MD&A text, while the newer filing excerpt contains primarily financial statements and notes; direct MD&A narrative comparison is limited
- Older filing is for nine-month period ended September 30, 2025; newer filing is for three-month period ended March 31, 2026 - different reporting periods make some comparisons not directly comparable
- The notes to financial statements in newer filing are truncated in the provided text, so complete note disclosure changes cannot be assessed
Risk Factors
- Added:
- New risk factor added in 2026-05-12 filing: 'We may engage in strategic transactions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources' covering acquisitions, debt issuance, equity dilution, integration risks, and management distraction
- Added in Item 5 (Other Information): disclosure about director and officer trading arrangements stating 'During our quarter ended March 31, 2026, none of our directors or executive officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement'
- Added to Item 6 (Exhibits): Exhibit 3.3 'Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated June 18, 2025'
- Signatures section added in 2026-05-12 filing with signatures of Shalabh Gupta (CEO, President, Chairman) and John Townsend (CFO) dated May 12, 2026
- Removed:
- Older filing (2025-11-12) contained extensive financial statements (Balance Sheets, Statements of Operations, Statements of Mezzanine Equity and Stockholders' Deficit, Statements of Cash Flows) that do not appear in the Risk Factors section of the newer filing
- Reworded:
- Header statement in newer filing states 'There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2025, except for the following:' indicating this 10-Q only adds new risk factors rather than restating all prior ones
- Notes:
- The older filing (2025-11-12) appears to be a full 10-Q with multiple sections including financial statements, while the newer filing excerpt (2026-05-12) shows only Items 1A through 6 of Part II of the 10-Q focusing on Risk Factors and other administrative items; direct comparison is limited to the Risk Factors section which exists in both filings
- The older filing shows only a table of contents for Item 1A (Risk Factors) with page references but does not include the full text of the risk factors themselves in the provided excerpt, making a complete Risk Factors comparison not fully assessable
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for UNCY — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding UNCY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 485,071
- Reported value $3,191,768
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
UNCY had 4,331,038 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
UNCY had 15.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.08 days to cover at the same settlement.
- Reported short interest (shares) 4,331,038
- Short interest (% of shares outstanding) 15.5%
- Prior settlement (shares) 4,939,936
- Reported change -12.33%
- Days to cover (reported) 5.08
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ardelyx (ARDX)
- Akebia Therapeutics (AKBA)
- Amgen (AMGN)
- Sanofi (SNY)
- Vifor Pharma
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare UNCY vs…
Frequently asked questions
What does UNICYCIVE THERAPEUTICS INC (UNCY) do?
Unicycive Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies for kidney disease. The company's pipeline consists of two main programs: oxylanthanum carbonate, a next-generation phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate for acute kidney injury treatment.
What sector is UNICYCIVE THERAPEUTICS INC (UNCY) in?
UNICYCIVE THERAPEUTICS INC (UNCY) is classified in the Health Care sector. Its industry is Clinical-stage kidney disease therapeutics. It trades on NASDAQ.
Does UNCY pay a dividend?
Yes — UNICYCIVE THERAPEUTICS INC (UNCY) pays a dividend (market data, as of 2026-08-24). Informational only — not financial advice.
Who are UNICYCIVE THERAPEUTICS INC's (UNCY) competitors?
Notable peers of UNICYCIVE THERAPEUTICS INC (UNCY) include Ardelyx, Akebia Therapeutics, Amgen, Sanofi and Vifor Pharma. This peer set is informational only — not financial advice.
Is UNICYCIVE THERAPEUTICS INC (UNCY) overbought or oversold right now?
UNICYCIVE THERAPEUTICS INC (UNCY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on UNCY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.